Stocks · Health care · Biological Products, (No Diagnostic Substances)

Replimune Group, Inc.

REPL Clue Score21

United States Fiscal year ends March CIK 0001737953 Results filed 28 Oct 2026

Add to watchlist

What the insiders did Net selling

Insider

Date

Role

Action

Price

Amount

Christopher Sarchi

1 Jun 2026

Chief Commercial Officer

Sold on a plan

12,000

$9.24

$110.88K

Christopher Sarchi

2 Apr 2026

Chief Commercial Officer

Sold on a plan

6,500

$8.01

$52.07K

Sushil Patel

2 Dec 2025

Chief Executive Officer

Sold on a plan

10,000

$11.13

$111.30K

Form 4 filings counted 40

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 2

Sales on a Rule 10b5-1 plan 3

Sales straight out of an exercise 2

Sales at will 13

Transactions with no price 0

Shares from compensation/vesting 974,245

History held since 25 Jul 2018